Structural basis for urate recognition and apigenin inhibition of human GLUT9

Nat Commun. 2024 Jun 12;15(1):5039. doi: 10.1038/s41467-024-49420-9.

Abstract

Urate, the physiological form of uric acid and a potent antioxidant in serum, plays a pivotal role in scavenging reactive oxygen species. Yet excessive accumulation of urate, known as hyperuricemia, is the primary risk factor for the development of gout. The high-capacity urate transporter GLUT9 represents a promising target for gout treatment. Here, we present cryo-electron microscopy structures of human GLUT9 in complex with urate or its inhibitor apigenin at overall resolutions of 3.5 Å and 3.3 Å, respectively. In both structures, GLUT9 exhibits an inward open conformation, wherein the substrate binding pocket faces the intracellular side. These structures unveil the molecular basis for GLUT9's substrate preference of urate over glucose, and show that apigenin acts as a competitive inhibitor by occupying the substrate binding site. Our findings provide critical information for the development of specific inhibitors targeting GLUT9 as potential therapeutics for gout and hyperuricemia.

MeSH terms

  • Apigenin* / chemistry
  • Apigenin* / pharmacology
  • Binding Sites
  • Cryoelectron Microscopy*
  • Glucose Transport Proteins, Facilitative* / antagonists & inhibitors
  • Glucose Transport Proteins, Facilitative* / chemistry
  • Glucose Transport Proteins, Facilitative* / metabolism
  • Gout / drug therapy
  • Gout / metabolism
  • HEK293 Cells
  • Humans
  • Hyperuricemia / drug therapy
  • Hyperuricemia / metabolism
  • Models, Molecular
  • Protein Binding
  • Uric Acid* / chemistry
  • Uric Acid* / metabolism

Substances

  • Glucose Transport Proteins, Facilitative
  • SLC2A9 protein, human
  • Uric Acid
  • Apigenin